COMPANY

AeroRx Therapeutics

HQ: La Jolla, CA source · aerorxtx.com ↗

AeroRx Therapeutics is developing potential nebulized combination therapies to improve chronic obstructive pulmonary disease (COPD) treatment. From company website Source · Oct 12, 2026

Keywords: COPD (Chronic Obstructive Pulmonary Disease) COPD AERO-002 AERO-001 AERO-007

Location: La Jolla, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

2026-09 Trial start 1: Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients source ↗
Jan 15, 2025 Trial start 1: Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD source ↗

Upcoming milestones

2026-12 (ESTIMATED) · 1 · Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients · NCT07802730

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07802730	Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients	1	Not yet recruiting	2026-09	2026-12 (estimated)
NCT06841640	Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD	1	Completed	Jan 15, 2025	May 20, 2025 (actual)